Test-Retest Reliability of the WB6Dim Digital Well-Being Tool: A 3-Day Interval Study
ConditionPsychological Well Being
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorClover Link
About this trial
This study aims to establish the test-retest reliability of the WB6Dim digital self-assessment tool across its eight well-being dimensions, using a 3-day interval protocol designed to minimize the probability of genuine well-being changes between assessments.
Participants complete the 28-item WB6Dim questionnaire at baseline (T1) and again 3 days later (T2). A single contamination control question at T2 identifies participants who experienced a significant life event during the interval; these pairs are excluded from primary ICC analyses and retained for exploratory analyses.
An optional third assessment at 9 weeks (T3) provides preliminary exploratory data on sensitivity to change following access to a well-being program. T3 is not part of the primary design.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Adults aged 18 years or older
Able to read and understand French
Access to an internet-connected device
Willing to complete the WB6Dim questionnaire at T1 and T2
Disqualifiers
Under 18 years of age
Unable to read or understand French
Trial population
Adult volunteers recruited from a French health and well-being newsletter subscriber base. Not selected based on medical conditions. Represents the general adult population with an interest in personal well-being and health prevention.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
500 Participants
are grouped into 1 trial groupGroup A: Cohort C - Test-Retest Reliability
Trial outcomes
Primary outcomes
1
Test-Retest Reliability (ICC) of the WB6Dim Internal Tension Dimension
ICC(1,1) on contamination-free T1/T2 pairs. Score range: 0 to 1. Higher values indicate greater temporal stability.
Time frame
Day 0 to Day 32
Test-Retest Reliability (ICC) of the WB6Dim Sleep and Recovery Dimension
ICC(1,1) on contamination-free T1/T2 pairs. Score range: 0 to 1. Higher values indicate greater temporal stability.
Time frame
Day 0 to Day 33
Test-Retest Reliability (ICC) of the WB6Dim Energy Reservoir Dimension
ICC(1,1) on contamination-free T1/T2 pairs. Score range: 0 to 1. Higher values indicate greater temporal stability.
Time frame
Day 0 to Day 34
Test-Retest Reliability (ICC) of the WB6Dim Self-Esteem Dimension
ICC(1,1) on contamination-free T1/T2 pairs. Score range: 0 to 1. Higher values indicate greater temporal stability.
Time frame
Day 0 to Day 3Secondary outcomes
1
Contamination Rate at T2
Proportion of T1/T2 pairs excluded due to a significant life event reported at T2 contamination control question. Reported as percentage.
Time frame
Day 32
ICC Comparison Between Contamination-Free and Contaminated Pairs
Exploratory comparison of ICC(1,1) estimates across all 8 WB6Dim dimensions between contamination-free and contaminated pairs, to assess direction and magnitude of contamination effects.
Time frame
Day 0 to Day 3Other outcomes
1
Exploratory Sensitivity to Change - Sleep and Recovery
Pre-post change score (T1 to T3) and Cohen's d for the Sleep and Recovery dimension, among participants who completed the 9-week follow-up. Reported descriptively if N≥30.
Time frame
Day 0 to Week 92
Exploratory Sensitivity to Change - Internal Tension
Pre-post change score (T1 to T3) and Cohen's d for the Internal Tension dimension, among participants who completed the 9-week follow-up. Reported descriptively if N≥30.
Time frame
Day 0 to Week 93
Exploratory Sensitivity to Change - Energy Reservoir
Pre-post change score (T1 to T3) and Cohen's d for the Energy Reservoir dimension, among participants who completed the 9-week follow-up. Reported descriptively if N≥30.
Time frame
Day 0 to Week 94
Exploratory Sensitivity to Change - Self-Esteem
Pre-post change score (T1 to T3) and Cohen's d for the Self-Esteem dimension, among participants who completed the 9-week follow-up. Reported descriptively if N≥30.
Time frame
Day 0 to Week 9Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov